Show simple item record

dc.contributor.authorRodriguez-Santana, Idaira
dc.contributor.authorDasMahapatra, Pronabesh
dc.contributor.authorBurke, Tom
dc.contributor.authorHakimi, Zalmai
dc.contributor.authorBartelt-Hofer, José
dc.contributor.authorNazir, Jameel
dc.contributor.authorO'Hara, Jamie
dc.identifier.citationRodriguez-Santana, I., DasMahapatra, P., Burke, T., Hakimi, Z., Bartelt-Hofer, J., Nazir, J., & O'Hara, J. (2022). Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study. Orphanet Journal of Rare Diseases, 17(1), 150.
dc.descriptionFrom Europe PMC via Jisc Publications Router
dc.descriptionHistory: ppub 2022-04-01, epub 2022-04-04
dc.descriptionPublication status: Published
dc.descriptionFunder: Sanofi
dc.description.abstractBackground: Haemophilia bears substantial humanistic and economic burden on children and their caregivers. Characterising the differential impact of severe versus moderate paediatric haemophilia is important for clinical and health policy decisions. We analysed health-related quality of life (HRQoL), annual direct medical (excluding factor treatment costs), non-medical and societal costs among children and adolescents with moderate and severe haemophilia A or B without inhibitors from the European CHESS-PAEDs study. Information was reported by physicians and caregivers; patients aged ≥ 8 years self-reported their HRQoL. Descriptive statistics summarised demographic and clinical characteristics, costs, and HRQoL scores (EQ-5D-Y). Regression models estimated differences in HRQoL and costs for moderate versus severe haemophilia adjusting for age, body mass index z-score, country, number of comorbidities, and weight-adjusted annual clotting factor consumption. Results: The analytic sample comprised 794 patients with a mean age of 10.5 years; most had haemophilia A (79%) and 58% had severe haemophilia. Mean predicted direct medical costs in moderate patients were two-thirds of the predicted costs for severe disease (€3065 vs. €2047; p < 0.001; N = 794), while societal costs were more than half of the predicted costs for children with severe haemophilia (€6950 vs. €3666; p < 0.001; N = 220). Mean predicted HRQoL scores were 0.74 and 0.69 for moderate and severe disease, respectively (p < 0.05; N = 185). Conclusion: Children with haemophilia and their caregivers displayed a significant economic and humanistic burden. While severe patients showed the highest direct medical and societal costs, and worse HRQoL, the burden of moderate haemophilia on its own was substantial and far from negligible.
dc.rightsLicence for this article: cc by
dc.sourcenlmid: 101266602
dc.sourceessn: 1750-1172
dc.sourceissn: 1750-1172
dc.subjectHaemophilia A
dc.subjectQuality of life
dc.subjectDirect Medical Costs
dc.subjectHaemophilia B
dc.subjectSocietal Costs
dc.subjectHemophilia A
dc.subjectCross-Sectional Studies
dc.subjectCost of Illness
dc.subjectQuality of Life
dc.subjectSurveys and Questionnaires
dc.titleHealth-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study.
dc.contributor.departmentHCD Economics, Daresbury; Sanofi Genzyme; University of Chester; Sobi, Stockholm; Sanofi, Chilly-Marzin

Files in this item


This item appears in the following Collection(s)

Show simple item record

Licence for this article: cc by
Except where otherwise noted, this item's license is described as Licence for this article: cc by